ArticleIntensive care medicine2008
High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis.
Article in Intensive care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- HMGB1-Platelet Interactions: Mechanisms and Targeted Therapy Strategies.Thrombosis and haemostasis · 2026Review
- Clinical practice of sepsis-induced immunosuppression: Current immunotherapy and future options.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2024Review
- Destabilisation of T cell-dependent humoral immunity in sepsis.Clinical science (London, England : 1979) · 2024Review
- The emerging roles and therapeutic potential of B cells in sepsis.Frontiers in pharmacology · 2022Review
- High Mobility Group Proteins in Sepsis.Frontiers in immunology · 2022Review
- Anti-Septic Potential of 7-α-Obacunyl Acetate Isolated from theInfection and drug resistance · 2021Article
- Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.Gene regulation and systems biology · 2017Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.Expert review of clinical immunology · 2014Review
- Targeting HMGB1 in the treatment of sepsis.Expert opinion on therapeutic targets · 2014Review
- Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.Critical care (London, England) · 2012Review
- Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Presence of preexisting antibodies mediates survival in sepsis.Shock (Augusta, Ga.) · 2012Article
- Article
- Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsis.PloS one · 2011Article
- HMGB1 is a therapeutic target for sterile inflammation and infection.Annual review of immunology · 2011Review
- Role of Apoptosis in Amplifying Inflammatory Responses in Lung Diseases.Journal of cell death · 2010Article
- High-mobility-group box chromosomal protein 1 as a new target for modulating stress response.Surgery today · 2010Review
- Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.Intensive care medicine · 2010Article
- High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.Inflammation & allergy drug targets · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntravenous immunoglobulin therapy has been proposed as an advanced treatment for sepsis. Yet, its benefit remains unclear and the mechanism of action is poorly understood. One key mediator in the development of sepsis is high mobility group box 1 (HMGB1). Therefore, we examined the serum and lung tissue levels of HMGB1 in a rat model of sepsis. DESIGN AND
settingProspective controlled animal study in a university laboratory. MATERIALS: Rats received either cecal ligation and puncture-induced sepsis or had additional intravenous immunoglobulin treatment in boluses of 100, 300, or 1,000 mg/kg. MEASUREMENTS AND
resultsAfter induction of sepsis and respective treatment conditions, histopathology, wet/dry weight ratios, and signaling molecules were examined in pulmonary tissue. Serum and pulmonary levels of cytokine and HMGB1 were measured. High dose intravenous immunoglobulin (1,000 mg/kg)-treated animals demonstrated significantly improved survival and pulmonary histopathology compared to the control rats. Serum and pulmonary HMGB1 levels were lower over time among intravenous immunoglobulin-treated animals. Furthermore, administration of intravenous immunoglobulin resulted in inhibition of NF-kappaB activity.
conclusionsHigh-dose intravenous immunoglobulin decreased the mortality and pulmonary pathology in a rat model of sepsis. A significant reduction in HMGB1 levels was also observed, which may be mediated by inhibition of inflammation and NF-kappaB. DESCRIPTOR: 23. Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI): experimental models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.